

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2005)

POSITIVE PROFIT ALERT

This announcement is made by the Company pursuant to Rule 13.09(2)(a) of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the SFO.

The Board wishes to inform the Shareholders and potential investors that, based on a preliminary review of the Company's unaudited consolidated management accounts for the six months ended 30 June 2017, the profit attributable to equity holders of the Company for the six months ended 30 June 2017 is expected to increase significantly and record an increase of not less than 30% as compared with that of the same period of 2016.

The information contained in this announcement is only based on a preliminary review of the Company's unaudited consolidated management accounts for the six months ended 30 June 2017. Such management accounts have not been reviewed by the auditor or the audit committee of the Company.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by SSY Group Limited (the "Company", together with its subsidiaries, collectively the "Group") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO").

The board of directors (the “Board”) of the Company wishes to inform the shareholders of the Company (the “Shareholders”) and potential investors that, based on a preliminary review of the Company’s unaudited consolidated management accounts for the six months ended 30 June 2017, the profit attributable to equity holders of the Company for the six months ended 30 June 2017 is expected to increase significantly and record an increase of not less than 30% as compared with that of the same period of 2016. Such expected increase was mainly due to, among other things, (i) increases in sales volumes and average selling prices of intravenous infusion solutions, (ii) increase in the overall gross profit margin of the Group’s products and (iii) the absence of expense for grant of options during the six months ended 30 June 2017, whereas there was a one-off expense incurred during the six months ended 30 June 2016 on grant of share options.

The information contained in this announcement is only based on a preliminary review of the Company’s unaudited consolidated management accounts for the six months ended 30 June 2017 and the information currently available to the Board. It is not based on any figures or information that have been reviewed by the Company’s auditor, or reviewed by the audit committee of the Company. The Company is still in the process of finalising the consolidated interim results of the Group for the six months ended 30 June 2017. The finalised consolidated interim results and other details of the Group for the six months ended 30 June 2017 will be published by the Company within the timeframe as stipulated under the Listing Rules.

Shareholders and potential investors are advised to read this announcement carefully and exercise caution when dealing in the shares of the Company.

By Order of the Board
Chow Hing Yeung
Company Secretary

Hong Kong, 1 August 2017

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.